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ABSTRACT 
 
Background 
The use of patient-reported outcome measures in electronic format has been 
increasing. However, these formats are usually not validated or compared to the 
original paper-based formats, so there is no evidence that they are completed in the 
same way. 
 
Objectives 
The aim of this study was to compare the conventional paper version and a web-
based application version (iPad®) of the DLQI to assess equivalence of scores.  
 
Methods 
The study employed a randomized cross-over design using a within-subjects 
comparison of the two formats of the questionnaire. International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) guidelines were followed. 
Subjects aged over 18 years with any confirmed skin condition were recruited from a 
teaching hospital dermatology outpatient clinic. Expected Intra-class correlation 
coefficient (ICC) was 0.9 (α = 0.05) 
 
Results 
A total of 104 patients were recruited, median age=53.5 years (IQR=37.3-67.8, 43% 
male). The Intraclass correlation coefficient (ICC) showed high concordance 
between the total DLQI scores from paper and iPad® versions (ICC = 0.98; 95% CI 
0.97-0.99). Patients took a median of 78 seconds to complete the electronic version 
and 73 seconds for paper (p=0.008): 76% preferred the electronic version and 
perceived completion to take a shorter time. 
 
Conclusions 
There is high concordance, and thus equivalence, between the iPad and paper 
versions of the DLQI, with an ICC of 0.98, and a clear patient preference for the iPad 
version. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4 
 
 
 
INTRODUCTION 
 
There is increasing interest in utilising technology within clinical medicine: 
innovations include computerised data entry1,2, communication initiatives3 and virtual 
reality4. Within dermatology, there have been several innovations using electronics 
and information technology5-7. The use of patient reported outcome measures 
(PROs) in electronic format has also been increasing8. However, these formats are 
usually not validated or compared to their original paper-based versions. This may 
result in data that is incomparable between the two formats due to the lack of 
equivalence9. Coons et al.10 have proposed guidelines detailing the level of evidence 
required to demonstrate equivalence, depending on the amount of modification to 
the original PRO.  
 
The Dermatology Life Quality Index (DLQI)11 is the most commonly used 
dermatology-specific quality of life (QoL) measure in clinical trials12-14. The DLQI is 
easy to use in clinical practice due to its brevity and simplicity15 with an average 
completion time of two minutes16. In the current era of widespread use of digital 
devices such as Tablets and smartphones, clinicians, researchers and patients often 
substitute non-validated electronic versions in place of the original paper version. 
However, there is an underlying concern whether such data is comparable to two 
decades of data gathered via the validated paper DLQI,11,14 posing several 
challenges in data analysis and interpretation. The availability of a DLQI application 
that had been validated would alleviate such concerns and contribute to better 
management of patients with skin conditions by having an easy tool for regular 
monitoring of disease severity from the patient’s own perspective. Moreover, this tool 
could potentially be used by general practitioners to decide which patients need to 
be referred, as well as provide reassurance for users of electronic QoL measures 
across dermatology and other medical fields. 
 
This study aimed at comparing the conventional paper-based and a novel web-
based application version of the DLQI, following International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) guidelines10, concerning 
patient acceptability and preference and in terms of consistency of scores. We also 
assessed whether there was a carryover effect depending on which format patients 
completed first (paper versus iPad). 
 
 
METHODS 
 
Study participants 
 
The study employed a randomized cross-over design using a within-subjects 
comparison of the two formats of the questionnaire. The study was conducted at the 
Dermatology outpatient department, University Hospital of Wales, Cardiff, UK. 
Inclusion criteria were: patients aged 18 years or older with any confirmed skin 
condition and the ability to read and understand English. The exclusion criteria were 
patients who were not able to read and or understand written English, or having a 
co-existing medical or second dermatological condition of considerable severity as 
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determined by the investigator, or physical deformities which would prevent writing or 
use of an iPad. The study protocol was approved by a local Ethics Committee (Ref: 
14/SW/0085, NRES Committee, South West-Central Bristol, UK) and the Cardiff and 
Vale University Health Board Research & Development Department. Written 
informed consent was completed by each subject prior to entering the study.   
 
The Dermatology Life Quality Index iPad® App 
 
The DLQI consists of 10 questions concerning a dermatological patient’s perception 
of the impact of their skin disease on different aspects of their QoL over the last 
week.  The items of the DLQI include symptoms and feelings, daily activities, leisure, 
work or school, personal relationships and the side effects of treatment.  Each item is 
scored on a 4-point scale: not at all/not relevant, a little, a lot and very much.  Scores 
of individual items (0-3) are added to yield a total score (0-30); higher scores mean 
greater impairment of patient’s QoL. The DLQI has been shown to be a strong 
instrument with respect to its internal consistency, reproducibility, validity and 
sensitivity to change14,15,17-19. 
 
The DLQI was developed into an electronic application on the iPad® by Janssen 
EMEA® in conjunction with the original copyright holder (AYF, Cardiff University). 
Only this particular iOS version was tested for the purpose of studying equivalence. 
The individual items and their response categories/scale were unchanged, allowing 
users to select options using touch. The application (Psoriasis 360©) is available 
without charge and may be downloaded from the Apple App Store: 
https://appsto.re/gb/-JIFw.i. It is also available on the Google (Android) App Store: 
https://play.google.com/store/apps/details?id=com.sapnagroup.p360&hl=en_GB. 
Example screenshots of the paper and iPad app versions are given in Figures 1a 
and 1b respectively. 
 
Study procedure 
 
Eligible patients were asked to complete the DLQI (both paper and electronic 
versions). The order of completing of the questionnaires (paper version first versus 
an iPad® version first) was randomized using a random number generator. After 30 
minutes patients were asked to complete the other format (Figure 2). Thirty minutes 
interval was used to minimise patient waiting time and burden, as following up 
patients to complete the study at a later date would result in a higher cost and 
increase the chances of change in disease severity10. The research team ensured 
that patients read a magazine, talked to staff or used their phones to browse in 
between testing as forms of distraction. 
Training to operate the electronic application was given in person to every subject by 
a member of the research team, who remained with the patient throughout the 
duration of completion in case the subject needed assistance. The electronic 
application also has basic instructions on the home screen and all patients were 
given time to read this prior to completion. Prior to completing either format of the 
DLQI, patients also completed a short demographic questionnaire on age, gender, 
literacy levels, visual and tactile impairments, diagnosis, and previous use of tablet 
computers or the DLQI. Completion of both versions were conducted in a similar 
environment, both completions for the same subject were either before or after 
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meeting the doctor, in order to reduce the effect of the doctor’s consultation upon 
patient reported QoL. The time taken by participants to complete the DLQI using the 
paper version and the application was recorded. Patients were asked to also 
complete a short questionnaire asking about their perception, attitude and 
experience with the paper-based and web-based methods, concerning ease or 
difficulty of administration, acceptability, time requirement, feasibility and being 
comfortable with disclosing personal information using the novel application-based 
method.  
 
Sample Size 
 
Sample size was calculated in accordance to ISPOR guidelines10. The study power 
was set at 95%, with an expected intra-class correlation coefficient (ICC) of 0.9 (α = 
0.05), resulting in a target sample size of 104 patients. 
 
Data analysis 
 
Data analysis was conducted using SPSS version 20®. The concordance of DLQI 
scores between paper-based and the application-based data was analysed using a 
two way fixed effects ICC model, which is the most commonly utilised statistical 
measure in equivalence studies of this nature20. Wilcoxon signed rank test was used 
to compare DLQI scores and completion times between the two formats; both 
variables were found to be non-normally distributed using Shapiro-wilk. A more 
stringent score difference of 1 point (3%) between the two versions was considered 
equivalent, though a majority of studies target a maximum of 5% difference20. Sub-
analysis was conducted to identify any carryover effect depending on which format of 
the DLQI patients completed first. Bland-Altman plots were drawn to measure the 
limits of agreement between the two formats. Equivalence was considered with limits 
of agreement <= 4, which is the minimal clinically important difference (MCID) for the 
DLQI21. 
 
Descriptive analysis was used to present demographic data of the patients and their 
feedback on the preference and experience of using the tools. Linear regression 
techniques were used to identify correlation of iPad completion times with age. 
 
 
RESULTS 
 
Socio-demographic characteristics of the study participants 
 
A total of 104 patients were recruited, mean age 52 years (SD ± 18.7, 43% male): 
demographic details are given in Table 1. The most common diagnoses were 
psoriasis (39%), ‘skin lesion’ (19%) and eczema (13%). The majority of patients 
(61%) had their highest level of education at school. 17% of patients had never used 
a tablet before and 46% stated that they were “a little” or “not” comfortable with a 
tablet prior to participating in this study.  
 
Comparisons of validity and reliability 
 
As shown in Table 2a, the ICC shows high concordance between the total DLQI 
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scores from paper and iPad® versions (ICC = 0.98; 95% CI 0.97-0.99). The median 
difference of scores was also within the hypothesized difference of ±1 point 
(p=0.006, Figure 3). The lower and higher limits of agreement were -3.1 and 4.1, 
respectively (Figure 4). Patients took a slightly longer time to complete the DLQI on 
the iPad® than on paper. The median of the individual time differences was 9 
seconds (IQR=-25-13 seconds, p=0.008). However, as shown in Table 2b, there was 
no carryover effect on scores (p=0.56) or completion times (p=0.76) regardless of 
which format of the DLQI was used first. Linear regression demonstrated that the 
time taken to complete the iPad version was weakly correlated in a positive way with 
age, with older patients taking slightly longer (R2=0.257, p=0.012). The estimated 
increase was 7.99 seconds for each 10 year increase in age. 
 
Comparisons of applicability and practicality 
 
Patients were asked: ‘On a scale of 1 to 10, where 1 is very uncomfortable and 10 is 
very comfortable, how comfortable were you using the iPad application version of the 
DLQI?’. In addition patients were also asked: ‘On a scale of 1 to 10, where 1 is very 
difficult and 10 is very easy, how easy did you find it to use the iPad application 
version of the DLQI?’. Both questions were also asked about the paper version of 
the DLQI. Patients found both paper and iPad® versions were easy (mean 9.4 ± 1.3 
for paper and 9.6 ± 1.3 for iPad®) and comfortable to use (mean 9.4 ± 1.1 for paper 
and 9.6 ± 1.4 for iPad®) (Table 3). Overall, 57% of patients reported perceived time 
to complete the iPad® version as shorter than that of the paper version. The format 
of the questionnaire used first has an effect on the perceived time of iPad® 
completion; more patients perceived shorter time with iPad® when paper was used 
first than when iPad® used first (70% vs. 43%; p=0.023). The feedback results in 
other areas were the same whether paper or iPad® was completed first. The 
majority of patients (76%) preferred iPad® over the paper version. The patients’ 
demographics or previous experience with Tablets did not have any effect on the 
choice of preference and completion of the questionnaire. 
 
 
DISCUSSION 
 
PROs are increasingly being used in electronic formats over their paper counterparts 
due to their inherent benefits, including a more streamlined process as well as 
increased reliability of data20. If not validated alongside the paper format, several 
new PROs are being validated initially in electronic format22, 23 to facilitate easier and 
higher quality data analysis and to reduce the overall cost of administration and 
storage. Paper-based instruments have a number of limitations such as higher rate 
of missing values, higher error rates in selecting multiple responses for single option 
items, data entry error24 in transferring responses from a paper form to the electronic 
databases and higher costs associated with administration, collection and 
processing the data25. These issues can be avoided by the use of computer-based 
administration (CBA) of QoL questionnaires.  
 
However, CBA of PROs presents several challenges26, 27. In routine clinical practice, 
assessment (at each visit) of disease severity and of QoL is labour intensive, 
requiring a major commitment of resources. Ease of use is one of the most important 
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factors necessary for assessing QoL as part of routine clinical practice. Furthermore, 
patients may not be accustomed to such input devices or may be hindered by the 
lack of Internet connectivity8. 
 
CBA of QoL measures such as in the form of web-based applications using 
touchscreen computers, also called Tablets (e.g. iPad®), is one of the ways that 
more frequent assessments can be conducted with minimal burden on patients and 
clinical staff in addition to meeting the requirements outlined above. This method, 
that includes not only CBA, but also scoring and presentation of QoL results, 
eliminates the need for a test (interviewer) administrator, as usually needed for 
traditional paper and pencil formats, while providing immediate "real-time" feedback. 
Information from assessments can be displayed in graphic reports as visual aids that 
help guide discussions about treatment options and care planning. The availability of 
electronic versions of QoL instruments on various computer-based devices has the 
potential to reduce both the respondent burden and administrative time required to 
transfer the results of these patient-reported outcomes e.g. QoL scores to the 
clinician’s desk enhancing the feasibility and logistics of integrating real-time QoL 
assessment data for immediate use into routine clinical care to aid decision-making. 
A further benefit of electronic data capture is the ability to record time and date 
stamps, in contrast to paper capture whereby completion may occur at a different 
time to that recorded or intended; a feature particularly useful for diary data. The 
computer-based measurement of QoL was well accepted by patients who felt that 
this method was a useful tool to inform the clinician about their problems28. Data are 
more complete on the electronic questionnaires compared with paper 
questionnaires, data handling is greatly simplified and the majority of patients prefer 
electronic completion29. The availability of an electronic format of the DLQI could 
potentially streamline referral systems from primary care, allowing more appropriate 
allocation of appointments and resources. For example, the DLQI is integral to 
guidelines assessing the severity of psoriasis30 and chronic hand eczema31 and 
referrals could potentially be triaged according to DLQI severity. In the research 
setting the availability of a web-based application would facilitate more efficient data 
collection in multicentre clinical trials and for longitudinal assessments of disease 
severity. 
In response to the increasing demand, a web-based application of the DLQI has 
been developed to encourage its further uptake in the current modernised clinical 
and research settings in many countries. Although computerised administration of 
QoL tools in other specialities has been shown to have numerous advantages over 
traditional paper-based tools32, this method of QoL assessment to present an overall 
disease severity idea has not yet been widely used in dermatology.  
 
Level of education and literacy are important to consider when conducting PRO 
studies33: this study is representative of the general population with the study 
subjects’ education ranging from secondary school (22.9%) to university level 
(37.6%). Previous experience with use of a Tablet device did not affect results, with 
17.3% of patients having never used one before and 46.2% stating that they were ‘a 
little comfortable’ or ‘not comfortable’ with using a Tablet. Overall, 76% of patients 
preferred the iPad version to the paper version, and found it easier to use and more 
comfortable. Furthermore, 93% of patients perceived that the iPad was quicker to 
complete or took the same time as the paper version, despite on average being 
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slower by a median of 9 seconds (p=<0.008). Similar findings have been reported in 
many studies comparing the electronic and paper PROs9, 20, 34. However, patients 
were aware they were being timed when completing both versions of the DLQI, 
which could be a potential source of bias. Slower completion times could also be 
attributed to the lack of familiarity of navigating on the iPad and occasional non-
responsiveness of the touch screen. Investigators reported that various patients did 
not know how to ‘touch’ the screen appropriately and often searched for a ‘next’ 
button rather than scrolling down, despite instructions provided to the user on every 
occasion. This may be attributed to a simple design flaw in the application itself 
whereby navigation may be updated to become more intuitive. This study indicates 
that patients enjoy using the iPad more and the extra time spent had a negligible 
impact on patient experience. One concern exhibited by a few patients included 
potential infection risk with shared iPads, though this may be less of an issue where 
personal electronic devices are used to monitor QoL changes over a period of time. 
 
There are some limitations to the study. For example, a 30 minutes washout period 
may be considered too short and result in a carryover, or ‘training’, effect, though 
there was no statistical evidence of this (Table 2b). Theoretically, this only may have 
occurred when the iPad was administered first, as patients spent longer on average 
completing it, therefore possibly having more time to remember the questions and 
answers. This effect however was counteracted by the cross-over study design, and 
reading material was provided to patients as a ‘distraction’. Nevertheless, there is no 
consensus on the ideal interval period between PRO administrations when carrying 
out test-retest validation: intervals used have ranged from one minute to seven 
years35. Other studies have also used 30 minutes as a washout period36. In order to 
reduce patient time and travel burden, as well as to ensure that disease severity did 
not fluctuate in between administrations, the shorter washout period of 30 minutes 
was used. Touch screen surfaces are also prone to accidental touches, which may 
result in unintentional item responses subsequently contributing to final score 
differences. The electronic version of the DLQI utilised in this study does not allow 
completion until all items are answered, which may impact validity if patients are 
coerced into answering questions they may have otherwise skipped on a paper 
format. This could have ethical implications from not giving patients the choice of not 
responding to a question if they do not wish to do so. In the DLQI, this issue is partly 
addressed by having a ‘not relevant’ option in eight of the ten questions. The median 
score difference of ‘0’  is unlikely to be clinically significant and strong correlation 
suggests that the two formats may be used interchangeably. Though the significant 
p-value of 0.006 for median total score difference is statistically significant, this is 
likely due to the large sample size37. Furthermore, the MCID for the DLQI is four21 
and therefore the difference in scores is negligible in a clinical context. The limits of 
agreement from the Bland-Altman plots (-3.4 to 4.1) are also similarly reassuring. 
Differential item functioning (DIF) was not assessed as the DLQI total score is most 
relevant in clinical decision-making14. 
 
Touchscreen devices offer many advantages including portability and real-time 
assessment of QoL status38. Though this study did not involve full psychometric 
evaluation of the DLQI, there is evidence to suggest that where minimal 
modifications have been made, psychometric properties remain intact and need not 
be tested again10, 20, 39. Whilst cognitive debriefing is suggested for equivalence 
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studies of electronic PROs where only minor modifications are made10, this 
requirement was circumvented by using a higher threshold for testing equivalence 
(i.e. by comparing scores). It is hoped this will provide further reassurance for users 
who may have had concerns regarding the validity of scores from the use of the 
DLQI in the previously non-validated electronic formats that have been used for 
many years.  Formally testing such measures in this novel format provides 
confidence for end users who might otherwise have been reluctant to consider use of 
such formats because of concerns about validity or applicability. Thus such studies 
may have wider and reassuring implications not just for the DLQI, but also for other 
PROs within dermatology and across other medical specialties, encouraging early 
simultaneous validation of electronic and paper versions. Several challenges remain, 
including interface design decisions, data collection40 and adapting electronic PROs 
to target populations, particularly in patients with physical disabilities or other 
impairments41. Nevertheless, this study has demonstrated that when the DLQI is 
migrated to an electronic format, the scores are equivalent, despite an overall slower 
completion time, which will become negligible with increased use and improvements 
to the application (app) interface. This study provides evidence of equivalence for 
this electronic application in particular (Psoriasis 360©), and future/other iterations of 
the electronic DLQI may not necessarily be equivalent. However, in most cases the 
changes to font size and layout are minor and thus repeated equivalence studies 
may be deemed unnecessary10. 
The majority of patients preferred the electronic DLQI over the paper format, 
reflecting the findings of many similar studies30, 42-43. This study demonstrates 
equivalence in the measurement properties of paper and electronic formats, 
providing confidence for the use of electronic format of the DLQI in both clinical and 
research settings, thereby paving the way for the digital era into current practices. 
The digital era in medicine will continue to be fuelled by a new generation of 
healthcare professionals who have been trained in this new platform. Patients and 
healthcare professionals are becoming more comfortable communicating and 
delivering their clinical expertise within a digital environment.  In this context the 
electronic DLQI would be a valuable instrument in professionals’ digital healthcare 
toolbox. 
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TABLES 
 
Table 1 Demographic characteristic of the study participants (DLQI study) 
 
 
All (n=104) Paper First (n=57) iPad First (n=47) 
Age  Mean ± sd 
Median (IQR) 
Min and max                         
(n=96) 
51.5 ± 18.7 
53.5 (37.3-67.8) 
20 - 89 
Mean ± sd 
Median (IQR) 
Min and max                        
(n=53) 
51.5 ± 19.3 
54 (33-68) 
20 - 89 
Mean ± sd 
Median (IQR) 
Min and max                         
(n=43) 
51.4 ± 18.2 
50 (38-67) 
20 - 85  
Sex Male 
Female 
43.3% (45) 
56.7% (59) 
Male 
Female 
50.9% (29) 
49.1% (28) 
Male 
Female 
34.0% (16) 
66.0% (31)  
Nationality British 
Other 
91.3% (95) 
8.7% (9) 
British 
Other 
91.2% (52) 
8.8% (5) 
British 
Other 
91.5% (43) 
8.5% (4) 
First 
Language 
English 
Welsh 
Other 
90.4% (94) 
1.9% (2) 
7.7% (8) 
English 
Welsh 
Other 
87.7% (50) 
3.5% (2) 
8.8% (5) 
English 
Welsh 
Other 
93.6% (44) 
- 
6.4% (3) 
Education Secondary School 
University 
60.6% (63) 
37.6% (41) 
Secondary School 
University 
57.9% (33) 
42.1% (24) 
Secondary School 
University 
63.8% (30) 
36.2% (17) 
Visual 
Impairment 
None 
Glasses 
Other condition 
Unspecified 
Missing data 
59.6% (62) 
29.8% (31) 
5.8% (6) 
1.9% (2) 
2.9% (3) 
None 
Glasses 
Other condition 
Unspecified 
Missing data 
64.9% (37) 
24.6% (14) 
5.3% (3) 
3.5% (2) 
1.8% (1) 
None 
Glasses 
Other condition 
Unspecified 
Missing data 
53.2% (25) 
36.2% (17) 
6.4% (3) 
- 
4.3% (2) 
Tactile 
Impairment 
Yes 
No 
9.6% (10)  
90.4% (94) 
Yes 
No 
8.8% (5) 
91.2% (52) 
Yes 
No 
10.6% (5) 
89.4% (42) 
Diagnosis Unknown 
Skin Lesion 
Psoriasis 
Eczema/Dermatitis 
Alopecia 
Vitiligo 
Infection 
Acne/Folliculitis 
Cyst 
Non-skin cancer 
Allergy 
Hidradenitis 
Autoimmune/infla
mmatory condition 
Missing data 
2.9% (3) 
19.2% (20) 
38.5% (40) 
13.5% (14) 
1.0% (1) 
1.9% (2) 
3.8% (4) 
6.7% (7) 
2.9% (3) 
1.9% (2) 
1.0% (1) 
1.9% (2) 
1.9% (2) 
… 
2.9% (3) 
Unknown 
Skin Lesion 
Psoriasis 
Eczema/Dermatitis 
Alopecia 
Vitiligo 
Infection 
Acne/Folliculitis 
Cyst 
Non-skin cancer 
Allergy 
Hidradenitis 
Autoimmune/infla
mmatory condition 
Missing data 
5.3% (3) 
22.8% (13) 
33.3% (19) 
14.0% (8) 
- 
1.8% (1) 
3.5% (2) 
5.3% (3) 
3.5% (2) 
1.8% (1) 
1.8% (1) 
3.5% (2) 
1.8% (1) 
… 
1.8% (1) 
Unknown 
Skin Lesion 
Psoriasis 
Eczema/Dermatitis 
Alopecia 
Vitiligo 
Infection 
Acne/Folliculitis 
Cyst 
Non-skin cancer 
Allergy 
Hidradenitis 
Autoimmune/infla
mmatory condition 
Missing data 
- 
14.9% (7) 
44.7% (21) 
12.8% (6) 
2.1% (1) 
2.1% (1) 
4.3% (2) 
8.5% (4) 
2.1% (1) 
2.1% (1) 
- 
- 
2.1% (1) 
… 
- 
Tablet Use Daily 
Less Often 
Never 
49.0% (51) 
32.7% (34) 
17.3% (18) 
Daily 
Less Often 
Never 
40.4% (23) 
43.9% (25) 
14.0% (8) 
Daily 
Less Often 
Never 
59.6% (28) 
19.1% (9) 
21.3% (10) 
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Missing data                   1.0% (1) Missing data                   1.8% (1) Missing data - 
Tablet 
Comfort 
Very Comfortable 
A Little Comfortable 
Not Comfortable      
Missing data                     
52.9% (55) 
30.8% (32)  
15.4% (16) 
1.0% (1) 
Very Comfortable 
A Little 
Comfortable 
Not Comfortable      
Missing data                     
54.4% (31) 
29.8% (17) 
 
14.0% (8) 
1.8% (1) 
Very Comfortable 
A Little 
Comfortable 
Not Comfortable      
Missing data 
51.1% (24) 
31.9% (15) 
 
17.0% (8) 
- 
Used DLQI 
before? 
Yes                            
No                      
Missing data                     
9.6% (10) 
89.4% (93) 
1.0% (1) 
Yes                            
No                      
Missing data 
7.0% (4) 
93.0% (53) 
- 
Yes                            
No                      
Missing data                     
12.8% (6) 
85.1% (40) 
2.1% (1) 
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Table 2a Equivalence analysis of paper and electronic DLQI overall mean scores and mean 
completion time 
 
 
    
 Paper iPad® ICC* 
(95% CI) 
Difference 
(P – I) 
Limits of 
agreement‡ 
DLQI scores 
(n=104) 
 lower upper 
Median (IQR)  5.0 (1-12) 4.0 (1-11) 0.98  
(0.97 – 
0.99) 
0.0 (0-1)† -3.1 4.1 
DLQI times 
(mins:seconds) 
 
Median (IQR) 1:13 
(00:56-
01:36) 
1:18 
(01:03- 
01:39) 
0.59  
(0.39 – 
0.72) 
-0:09 (00:25-
00:13)† 
  
 
CI = confidence interval, ICC = intraclass correlation, IQR = interquartile range, SD = 
standard deviation  
P-I = Paper - iPad® 
* Hypothesizing coefficient of ≥ 0.9 
† p value < 0.05 calculated by Wilcoxon Signed Rank test 
‡ Limits of agreement calculated from Bland-Altman plots (Figure 4) 
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Table 2b Equivalence and carryover analysis of paper and electronic DLQI 
 
 All (n=104) Paper First (n=57) iPad® First (n=47) 
Paper Score: 
Median (IQR) 
Min and max 
 
5 (1-12) 
0 – 30  
 
5 (1-12.5) 
0 - 26 
 
6 (1-12) 
0 – 30 
iPad® Score:  
Median (IQR) 
Min and max 
 
4 (1-11) 
0 - 27 
 
4 (0.5-10) 
0 - 26 
 
6 (1-12) 
0 – 30 
Paper Time (mins:seconds):  
Median (IQR) 
Min and max 
 
01:13 (00:56-01:36) 
00:28 – 04:15  
 
01:24 (01:06-01:40) 
00:28 – 04:15  
 
01:03 (00:50-01:29) 
00:30 – 02:49 
iPad® Time (mins:seconds):  
Median (IQR) 
Min and max 
 
01:18 (01:03-01:39) 
00:35 – 08:24 
 
01:13 (00:58-01:27) 
00:35 – 08:24 
 
01:25 (01:09-01:53) 
00:49 – 02:49 
Score difference: 
Median (IQR) 
Min and max 
p value 
Carryover effect 
 
0 (0-1) 
(-3) – 11 
0.006† 
 
0 (0-1.5) 
(-2) -11 
 
 
0 (0-0) 
(-3) – 5 
 
0.56† 
Time difference (mins:seconds):  
Median (IQR) 
 
Min and max 
p value 
Carryover effect 
 
-00:09 (-00:25-
00:13) 
(-06:45) – 00:58 
0.008† 
 
00:09 (-00:09-
00:23.5) 
(-06:45) – 00:58 
 
 
-00:26 (-00:46- 
-00:11) 
(-01:53) – 00:16 
 
0.76† 
 
† p-value calculated by Wilcoxon Signed Rank test 
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Table 3 Comparisons of applicability and practicality of paper and electronic versions 
of the DLQI 
 
 All (n=104) Paper First (n=57) iPad® First (n=47) 
 Paper iPad® Paper iPad® iPad® Paper 
Ease of use: 
Median  
(IQR) 
 
10 
(9-10) 
 
10 
(10-10) 
 
10 
(10-10) 
 
10 
(10-10) 
 
10 
(9-10) 
 
10 
(9-10) 
Comfort:  
Median 
(IQR) 
 
10 
(9-10) 
 
10 
(10-10) 
 
10 
(9-10) 
 
10 
(10-10) 
 
10 
(10-10) 
 
10 
(9-10) 
Perceived time to 
complete iPad® 
 Shorter than paper     
The same as paper     
Longer than paper      
Missing data                
  
 
57.7% (60) 
35.6% (37) 
5.8%   (6) 
1.0%   (1) 
 
 
70.2% (40) 
26.3% (15) 
3.5% (2) 
- 
 
 
42.6% (20) 
46.8% (22) 
8.5% (4) 
2.1% (1) 
Preference  
Paper                   
iPad® 
No preference              
 
13.5% (14) 
76.0% (79) 
10.6% (11) 
 
15.8% (9) 
75.4% (43) 
8.8% (5) 
 
10.6% (5) 
76.6% (36) 
12.8% (6) 
 
Score: 10 = very easy or very comfortable, 1 = very difficult or very uncomfortable 
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Figures 
 
Figure 1a The original DLQI questionnaire11 
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Figure 1b Example screenshot from the DLQI iPad app  
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Figure 2 Flow diagram of the study procedure  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawn (n = 5) 
Patients approached in 
Dermatology OPD (n = 497) 
Patients recruited for study        
(n = 109) 
Ineligible or declined (n = 
388) 
Completion of Paper DLQI 
second (n = 47) 
Randomised to complete 
Paper DLQI first (n = 57) 
Completion of iPad DLQI 
second (n = 57) 
Randomised to complete 
iPad DLQI first (n = 47) 
30-minute washout period 
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Figure 3 Box plot demonstrating the score distribution of both paper and iPad DLQI 
formats 
 
The bottom whisker represents the lowest value, and the upper whisker represents 
the highest value. The dot represents ‘one outlier’. The upper level of the box 
represents the 75th percentile and the lower level of the box represents the 25th 
percentile. The broad horizontal line in the middle of the box represents the median. 
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Figure 4 Bland-Altman plot demonstrating Paper and iPad DLQI score agreement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
